Tesla
TSLA
NVIDIA
NVDA
Palantir
PLTR
4
Apple
AAPL
5
Strategy
MSTR
US Stock MarketDetailed Quotes
FBLG FibroBiologics
- 1.050
- -0.060-5.41%
Trading Mar 11 10:05 ET
39.00MMarket Cap-2.00P/E (TTM)
1.110High1.050Low24.66KVolume1.100Open1.110Pre Close26.77KTurnover0.09%Turnover RatioLossP/E (Static)37.14MShares13.59052wk High14.19P/B28.71MFloat Cap0.98452wk Low--Dividend TTM27.35MShs Float55.000Historical High--Div YieldTTM5.38%Amplitude0.984Historical Low1.085Avg Price1Lot Size
FibroBiologics Stock Forum
filing of application for a patent
FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics
Tuesday, 4th March at 8:30 am
This innovative method has the potential to unlock new treatment options for chronic conditions driven by mitochondrial dysregulation.
HOUSTON, March 04, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ: FBLG) ("FibroBiologics") , a clinical-stage biotechnology company with 160+ patents issued and pending with a foc...
FibroBiologics and Charles River Announce Completion and Release of CYWC628 Master Cell Bank for the Manufacturing of Fibroblast Cell-based Wound Healing Therapeutic
Thursday, 27th February at 8:30 am
HOUSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (NASDAQ: FBLG) ("FibroBiologics") and Charles River Laboratories ("Charles River"), a leading, global provider of drug discovery, development, and manufacturing solutions, today announced the completion o...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER...
FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing
Monday, 30th December at 4:30 pm
HOUSTON, Dec. 30, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that it has closed the second $5...
Yorkville agreed to advance to FibroBiologics the first $15 million available und...
FibroBiologics Announces $25 Million Financing
Monday, 23rd December at 7:55 am
HOUSTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that it has entered into a Standby Equity Purchase Agreement (th...
No comment yet